I never stated or suggested that DCVax-l was going to get MHRA approval for all cancer-based tumors (though I speculate that there is a change that NWBO could be going for a cancer-agnostic designation, which would explain the effort/size of the SAP and MHRA application and well as the current MHRA delay in approval).
I simply made a statement, in the context of a Merck buyout, that DCVax-L worked against all tumor-based cancers, which is consistent with DCVax-L's mechanism of action. If DCVax-L, tomorrow or in 2 years, became THE effective treatment of all tumor-based cancers, that would be even more of an incentive for Merck to buy NWBO.
But this is all speculation from a person who knows little about this matter. Best of luck, sincerely, to all real, honest, decent investors. To the fudders, ... fill in the blank.
Market Data 
Markets 
AI
